CSI Market
Sign In | Register

Petros Pharmaceuticals inc (PTPI) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access PTPI quarterly Cash Flow →
Cash flow patterns shown here provide context for understanding Petros Pharmaceuticals inc's ability to sustain operations and capital deployment.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2020)
Operating Activities
Income1.91
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Intangible Assets, Finite-lived0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total-6.97
Share-based Compensation0.30
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-10.31
Inventory And Sample Inventory Reserve-
Adjustments For Deferred Revenue-
Gain Loss On Settlement With Vivus-
Employee Benefits And Share Based Compensation Noncash-
Derivative Gain Loss On Derivative Net-
Operating Income Loss From Continuing Operations10.42
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-0.68
Increase (Decrease) in Accrued Liabilities0.04
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.03
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities1.12
Discontinued operations-2.55
Net Cash flow from Operating Activities-6.73
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Warrant Deemed Dividend Income Statement Impact41.60
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-41.60
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock-0.34
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-5.14
Payment Of Senior Debt End Of Term Fee-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents5.14
Proceeds From Issuance Or Sale Of Equity Net8.50
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities8.16
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-6.73
Total Cash Flow1.43
4 historic quarters locked

Sign in to unlock the full Petros Pharmaceuticals inc cash flow history.

Sign In Create Free Account

About Petros Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-043822

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License